Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 949-955

  Satoh, Taroh ^a   Omuro, Yasushi ^b   Sasaki, Yasutsuna ^c   Hamamoto, Yasuo ^d   Boku, Narikazu ^e   Tamura, Takao ^f   Ohtsu, Atsushi ^g  

^a OSAKA UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^d TOCHIGI CANCER CENTER   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Advanced gastric cancer; Capecitabine; Cisplatin; Pharmacokinetics; ToGA study; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; JAPANESE; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMANS; JAPAN; MALE; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84859789267     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1783-9     Document Type: Article

References (25)

1. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267 (Pubitemid 27020582)
2. Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996-2004 (Pubitemid 34413593)
3. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991-4997 (Pubitemid 46631401)
4. Ajani JA (2008) Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer 113:945-955
5. Kim NK, Park YS, Heo DS et al (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3818
6. Ohtsu A, Shimada Y, Shirao K et al (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54-59
7. Ajani J (2000) Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 18:4001-4003
8. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
9. Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666-673
10. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
11. Pivot X, Chamorey E, Guardiola E et al (2003) Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 14:1578-1586 (Pubitemid 37304616)
12. Evans TR, Pentheroudakis G, Paul J et al (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with in operable oesophagogastric adenocarcinoma. Ann Oncol 13:1469-1478
13. Budman DR, Meropol NJ, Reigner B et al (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16:1795-1802
14. Mackean M, Planting A, Twelves C et al (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985 (Pubitemid 28417417)
15. Reigner B, Watanabe T, Schüller J et al (2003) Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 52:193-201 (Pubitemid 37204532)
16. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104 (Pubitemid 32242792)
17. Koizumi W, Saigenji K, Ujiie S et al (2003) A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64:232-236 (Pubitemid 36438808)
18. Villalona-Calero MA, Weiss GR, Burris HA et al (1999) Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 17:1915-1925 (Pubitemid 29269265)
19. Felici A, Loos WJ, Verweij J et al (2006) A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cancer Chemother Pharmacol 58:673-680 (Pubitemid 44167393)
20. Kitajima K, Fukuoka M, Kobayashi S et al (1987) Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity. Jpn J Cancer Chemother 14:2517-2523 (Pubitemid 18051281)
21. Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57:756-763 (Pubitemid 38748043)
22. Hanada K, Nishijima K, Ogata H et al (2001) Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol 31:179-184 (Pubitemid 32640364)
23. Cassidy J, Twelves C, Cameron D et al (1999) Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 44:453-460 (Pubitemid 29501014)
24. Reigner B, Clive S, Cassidy J et al (1999) Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol 43:309-315 (Pubitemid 29075888)
25. Pronk LC, Vasey P, Sparreboom A et al (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83:22-29 (Pubitemid 30352712)